Literature DB >> 2220309

Ventricle brain ratio in the clinical course of HIV infection.

A A Moeller1, H C Backmund.   

Abstract

As part of the computerized tomographic assessment of an unselected group of 47 patients in different stages of HIV infection we determined the ventricle brain ratio (VBR) and the width of several cortical sulci. We compared the findings for subgroups of patients defined by their stage in the Walter Reed Staging Classification. There was a significant increase in VBR only in the subgroup of patients with manifest acquired immune deficiency syndrome (AIDS) (WR 6). The findings are discussed in connection with the question of the likelihood that dementia will develop even in stages of HIV-infection preceding AIDS.

Entities:  

Mesh:

Year:  1990        PMID: 2220309     DOI: 10.1111/j.1600-0404.1990.tb01010.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment.

Authors:  V Di Sclafani; R D Mackay; D J Meyerhoff; D Norman; M W Weiner; G Fein
Journal:  J Int Neuropsychol Soc       Date:  1997-05       Impact factor: 2.892

2.  Subcortical brain atrophy persists even in HAART-regulated HIV disease.

Authors:  James T Becker; Joanne Sanders; Sarah K Madsen; Ann Ragin; Lawrence Kingsley; Victoria Maruca; Bruce Cohen; Karl Goodkin; Eileen Martin; Eric N Miller; Ned Sacktor; Jeffery R Alger; Peter B Barker; Priyanka Saharan; Owen T Carmichael; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2011-06       Impact factor: 3.978

3.  Cerebral atrophy in AIDS: a stereological study.

Authors:  S Oster; P Christoffersen; H J Gundersen; J O Nielsen; B Pakkenberg; C Pedersen
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  Nocturnal sleep EEG in patients with HIV infection.

Authors:  M Wiegand; A A Möller; W Schreiber; J C Krieg; D Fuchs; H Wachter; F Holsboer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.